Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY and GLENN LARKIN

Vertex Pharmaceuticals Stock Sees Composite Rating Edge Up To 96

On Tuesday, Vertex Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96.

The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. The top-performing stocks tend to have a 95 or better grade as they launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.

Vertex Pharmaceuticals is currently forming a second consecutive cup without handle, sometimes called a base-on-base, with a 325.29 entry. See if the stock can break out in volume at least 40% higher than normal, which it has not yet shown it can do.

Looking For The Best Stocks To Buy And Watch? Try These Exclusive Lists

 

The stock sports a 96 EPS Rating, which means its recent quarterly and longer-term annual earnings growth tops 96% of all stocks.

Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.

In Q4, the company posted 25% earnings-per-share growth. Sales growth fell to 11%, down from 18% in the prior quarter.

Vertex Pharmaceuticals holds the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals is the No. 1-ranked stock within the group.

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.